Advice
Following a full submission lacosamide (Vimpat) is accepted for restricted use within NHS Scotland as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.
The proportion of responders was significantly greater with adjunctive lacosamide treatment compared to placebo. Lacosamide use is restricted to patients with refractory epilepsy and treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy
Download detailed advice101KB (PDF)
Medicine details
- Medicine name:
- lacosamide (Vimpat)
- SMC ID:
- 532/09
- Indication:
- Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years or older
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 February 2009